Xvivo Perfusion AB Total Liabilities
Xvivo Perfusion AB total liabilities. Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has total liabilities worth Skr326.64 Million SEK (≈ $35.15 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XVIVO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Xvivo Perfusion AB (2011–2025)
Total liabilities of Xvivo Perfusion AB from 2011 to 2025. This chart illustrates how Xvivo Perfusion AB's total liabilities have evolved over time, based on quarterly financial data. Explore XVIVO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Xvivo Perfusion AB Competitors by Total Liabilities
The table below lists competitors of Xvivo Perfusion AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tropicana Corporation Bhd
KLSE:5401
|
Malaysia | RM6.00 Billion |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
China | CN¥672.43 Million |
|
Flexium Interconnect Inc
TW:6269
|
Taiwan | NT$13.05 Billion |
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.19 Billion |
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
China | CN¥658.60 Million |
|
Chimera Investment Corporation
NYSE:CIM
|
USA | $13.63 Billion |
|
Time Publishing and Media Co Ltd Class A
SHG:600551
|
China | CN¥2.50 Billion |
|
Legacy Housing Corp
NASDAQ:LEGH
|
USA | $53.41 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Xvivo Perfusion AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Xvivo Perfusion AB (XVIVO) total assets.
Liquidity & Leverage Metrics
Xvivo Perfusion AB Total Liabilities Ratios Explained
Xvivo Perfusion AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xvivo Perfusion AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xvivo Perfusion AB (2011–2025)
The table below shows the annual total liabilities of Xvivo Perfusion AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr260.65 Million ≈ $28.05 Million |
+5.97% |
| 2024-12-31 | Skr245.97 Million ≈ $26.47 Million |
-1.84% |
| 2023-12-31 | Skr250.57 Million ≈ $26.96 Million |
-17.29% |
| 2022-12-31 | Skr302.95 Million ≈ $32.60 Million |
+17.81% |
| 2021-12-31 | Skr257.15 Million ≈ $27.67 Million |
+81.28% |
| 2020-12-31 | Skr141.85 Million ≈ $15.27 Million |
+149.00% |
| 2019-12-31 | Skr56.97 Million ≈ $6.13 Million |
+23.48% |
| 2018-12-31 | Skr46.13 Million ≈ $4.96 Million |
+34.87% |
| 2017-12-31 | Skr34.21 Million ≈ $3.68 Million |
+4.03% |
| 2016-12-31 | Skr32.88 Million ≈ $3.54 Million |
+70.33% |
| 2015-12-31 | Skr19.31 Million ≈ $2.08 Million |
-24.34% |
| 2014-12-31 | Skr25.52 Million ≈ $2.75 Million |
-17.50% |
| 2013-12-31 | Skr30.93 Million ≈ $3.33 Million |
+20.10% |
| 2012-12-31 | Skr25.75 Million ≈ $2.77 Million |
-80.03% |
| 2011-12-31 | Skr128.97 Million ≈ $13.88 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more